作者 | 金钱草编辑 | 郑瑶2025年我国药品、医疗器械领域临床急需产品上市实现跨越式增长,其中1类创新药76个(如果瑞格列汀二甲双胍片(Ⅰ)、(Ⅱ)分开计算则为77个);创历史新高。此外,据笔者不完全统计,2类改良型新药获批34个(如果恒格列净瑞格列汀二甲双胍缓释片(Ⅰ)、(Ⅱ)分开计算则为35个)。为便于统计分析,则将前述(Ⅰ)、(Ⅱ)分开统计,合计为112个新药,本文试从品种分布、进入医保...
Source Link作者 | 金钱草编辑 | 郑瑶2025年我国药品、医疗器械领域临床急需产品上市实现跨越式增长,其中1类创新药76个(如果瑞格列汀二甲双胍片(Ⅰ)、(Ⅱ)分开计算则为77个);创历史新高。此外,据笔者不完全统计,2类改良型新药获批34个(如果恒格列净瑞格列汀二甲双胍缓释片(Ⅰ)、(Ⅱ)分开计算则为35个)。为便于统计分析,则将前述(Ⅰ)、(Ⅱ)分开统计,合计为112个新药,本文试从品种分布、进入医保...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.